Navigation Links
Grifols Establishes Expert Advisory Council in Transfusion Medicine
Date:3/7/2011

BARCELONA, Spain, March 7, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it has established an Expert Advisory Council in Transfusion Medicine drawing on the expertise of internationally renowned physicians and researchers from across the globe.  The role of the Expert Advisory Council is to provide insight, advice and guidance to Grifols' own transfusion medicine research and development activities.

(Logo: http://photos.prnewswire.com/prnh/20110304/PH59473LOGO)

"Bringing together these leaders in transfusion medicine underscores our longstanding commitment to being a world leader in blood diagnostics and transfusion medicine," said Eva Bastida, Ph.D, Scientific Director of Grifols. "Working with this team of experts will bring new perspectives to shape our strategic goals and plans," continued Dr. Bastida.  Grifols Diagnostics is focused on the development of cutting-edge technologies for use in clinical laboratories and blood banks.

"It is an honor to serve with my transfusion medicine colleagues on the Grifols Expert Advisory Council," said Mr. John Moulds, MT (ASCP) director of Scientific Support Services at LifeShare Blood Centers, Shreveport, Louisiana who serves as the Council Chair.  "Working with such a highly esteemed group of thought leaders will no doubt bear fruit that will help shape future directions in transfusion medicine," stated Mr. Moulds.  

Grifols has a seventy-year history of advancing blood diagnostics and transfusion medicine remains a core part of its business today.  With input from the Expert Advisory Council Grifols will continue to advance its mission of improving hemovigilance, transfusion safety, and the quality of life for people who receive blood transfusions.  The broad geographic diversity of Advisory Council members is expected to stimulate creative new approaches to current transfusion medicine challenges.  

Grifols portfolio of products and services cover every link of the transfusion chain: blood bags and donation kits, blood component separators, autoanalyzers and reagents for pre-transfusion analytical tests (blood typing and donor-recipient compatibility studies) and blood bank management software, among others.

Members of the Advisory CouncilThe Advisory Council is chaired by Mr. John Moulds, MT (ASCP) director of Scientific Support Services at LifeShare Blood Centers,  Shreveport, Louisiana, USA, and its membership consists of nine globally respected experts from different countries.  Members of the Grifols Advisory Council on Transfusion Medicine include:Dr. Jill R. Storry, Ph.D.Docent / Assoc. ProfessorKIT / Clinical Immunology and Transfusion Medicine Labmedicin Skane University and Regional Laboratories Lund - SWEDENProf. Dr. Lilian Castilho, PhDCoordinator, Blood Center of CampinasCEP Campinas SP  - BRAZILDr. Miquel Lozano, MD, PhDChief of the Hemotherapy Section of the Department of Hemotherapy and Hemostasis, Hospital Clinic of Barcelona, Barcelona, Spain.Dr. Arthur Bracey, MDMedical Director, Transfusion ServicesSt. Luke's Episcopal HospitalHouston, TX - USProf. W. John Judd, FIBMS, MIBiolPresident and CEOImmunohematology Consulting, LLCSupply, NC - USDr. Mark Yazer, MD FRCPCAssociate Professor of Pathology, University of PittsburghMedical Director, RBC Serology Reference Laboratory, Centralized Transfusion Service, The Institute for Transfusion MedicinePittsburgh, PA US Dr. Yoshihiko Tani, MD, PhDJapanese Red Cross Osaka Blood Center - JAPANProf. Neil AventHead of School School of Biomedical and Biological SciencesUniversity of Plymouth, Plymouth, UKDr. Jacques  Chiaroni Directeur de l'Etablissement Francais du Sang Alpes-MediterraneeMarseille, FRANCEAbout GrifolsGrifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 Grifols has been listed on the Spanish Continuous Market, and has been included in the Ibex-35 since 2008.  Grifols focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies.  In recent years Grifols has made significant investments in the area of transfusion medicine to advance its mission of improving hemovigilance, transfusion safety, and the quality of life for people who receive blood transfusions.  For more information visit www.grifols.com.


'/>"/>

SOURCE Grifols
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
4. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
5. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
6. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
7. Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US
8. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Pharmaxis Establishes Named Patient Program for Bronchitol
11. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Inc. today announced the appointment of Martyn Coombs as ... of ImaginAb, said "At ImaginAb we have exciting science and technology. ... our business, particularly in commercializing and making step changes in the ... realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear medicine and ...
(Date:3/22/2017)... N.J. , March 22, 2017  CANTEL MEDICAL CORP. ... B. Hansen , President and CEO, will be presenting at ... at the Westin Grand Central Hotel in New ... April 5, 2017 at 3:00 p.m. ET. In addition, management ... A live audio webcast will be available ...
(Date:3/22/2017)... 22, 2017 Research and Markets has ... Inhibitors Market & Clinical Pipeline Insight 2022" drug pipelines ... ... Clinical Pipeline Insight 2022 report gives comprehensive insight on clinical ... immune check point inhibitors as main streamline drugs in the ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March ... the coding audit process for all medical chart types with a comprehensive set ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To Atheist ... To Atheist Manifesto” is the creation of published author Richard Hostetter, a former ... years. He holds graduate degrees from Kent State University and the University of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... today announced the publication of “Profiling protein expression in circulating tumor cells using ... publication describes the use of the Vortex technology to capture CTCs ...
(Date:3/22/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had won the ‘Clinical Supply Chain Excellence’ category ... International Exhibition & Convention Centre, Singapore. The award was presented at the conference ...
Breaking Medicine News(10 mins):